ClinicalTrials.Veeva

Menu
A

Adams Clinical | Boston, MA

Research site

Site insights

Top conditions

Top treatments

Brenipatide
CYB003
MM120
Trontinemab
Azetukalner
Psilocybin
LY3537031
Alcohol
LSD D-Tartrate
LHP588

Parent organization

This site is a part of Adams Clinical

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

22 of 24 total trials

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (TRONTIER 2)

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild c...

Active, not recruiting
Alzheimers Disease
Drug: Trontinemab
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized A...

Active, not recruiting
Generalized Anxiety Disorder
Drug: DT120
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Enrolling
Major Depressive Disorder
Other: Placebo
Drug: DT120

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depress...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: DT120

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized...

Active, not recruiting
Generalized Anxiety Disorder
Drug: DT120
Other: Placebo

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Active, not recruiting
Major Depressive Disorder
Drug: Azetukalner
Drug: Placebo

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in pat...

Enrolling
Depression in Adults
Depression Disorders
Drug: CYB003
Behavioral: Psychological Support

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and...

Enrolling
Alcohol Use Disorder
Drug: Placebo
Drug: LY3537031

This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have sym...

Not yet enrolling
Major Depressive Disorder
Drug: Brenipatide
Drug: Placebo

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use...

Enrolling
Alcohol Use Disorder
Drug: LY3537031
Drug: Placebo

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when u...

Enrolling
Opioid Use Disorder
Drug: Brenipatide
Drug: Buprenorphine

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive sym...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but wit...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Trontinemab
Locations recently updated

This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, s...

Enrolling
Generalized Anxiety Disorder
Drug: SEP-363856
Other: Placebo

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Active, not recruiting
Major Depressive Disorder
Drug: Azetukalner

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-t...

Invitation-only
Major Depressive Disorder
Drug: CYB003

Trial sponsors

Lilly logo
D
C
Roche logo
Janssen (J&J Innovative Medicine) logo
X
C
Otsuka logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems